Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway

Molecular and Cellular Endocrinology

Volumn 393, Issue 1-2, 2014, Pages 152-163

  Joshi, Rashika ^a,b   Kadeer, Nijiati ^b   Sheriff, Sulaiman ^a   Friend, Lou Ann ^a,b   James, J Howard ^a,b   Balasubramaniam, Ambikaipakan ^a,b,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Burn injury; C2C12 myotubes; Muscle atrophy; PDE4; Signaling pathways; Torbafylline

Indexed keywords

CYCLIC AMP; ESI 09; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC AMP; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CYCLIC AMP INHIBITOR; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 6; LY 2904002; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN; PROTEIN INHIBITOR; PROTEIN KINASE B; TORBAFYLLINE; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; PDE4B PROTEIN, RAT; PENTOXIFYLLINE; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURN; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; IN VITRO STUDY; MALE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SKELETAL MUSCLE; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BURNS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; MALE; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; PENTOXIFYLLINE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE INHIBITORS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION;

EID: 84904055503     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.06.012     Document Type: Article

References (66)

1. Aili Low J.F., Barrow R.E., Mittendorfer B., Jeschke M.G., Chinkes D.L., Herndon D.N. The effect of short-term growth hormone treatment on growth and energy expenditure in burned children. Burns 2001, 27:447-452.
2. Almahariq M., Tsalkova T., Mei F.C., Chen H., Zhou J., Sastry S.K., Schwede F., Cheng X. A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol. Pharmacol. 2013, 83:122-128.
3. Balasubramaniam A., Joshi R., Sheriff S., Friend L.A., James J.H. Torbafylline (HWA 448) inhibits skeletal muscle proteolysis in burned rats (Abstract). J. Burn Care Rehabil. 2009, 30:S151.
4. Balasubramaniam A., Joshi R., Su C., Friend L.A., Sheriff S., Kagan R.J., James J.H. Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases, MuRF1 and MAFbx. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:R893-R901.
5. Baviera A.M., Zanon N.M., Carvalho Navegantes L.C., Migliorini R.H., do Carmo Kettelhut I. Pentoxifylline inhibits Ca2+-dependent and ATP proteasome-dependent proteolysis in skeletal muscle from acutely diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E702-E708.
6. Baviera A.M., Zanon N.M., Navegantes L.C., Kettelhut I.C. Involvement of cAMP/Epac/PI3K-dependent pathway in the antiproteolytic effect of epinephrine on rat skeletal muscle. Mol. Cell. Endocrinol. 2010, 315:104-112.
7. Beisel W.R. Herman Award Lecture, 1995: infection-induced malnutrition - from cholera to cytokines. Am. J. Clin. Nutr. 1995, 62:813-819.
8. Bistrian B.R., Schwartz J., Istfan N.W. Cytokines, muscle proteolysis, and the catabolic response to infection and inflammation. Proc. Soc. Exp. Biol. Med. 1992, 200:220-223.
9. Bloom T.J. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can. J. Physiol. Pharmacol. 2002, 80:1132-1135.
10. Brennesvik E.O., Ktori C., Ruzzin J., Jebens E., Shepherd P.R., Jensen J. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cell Signal. 2005, 17:1551-1559.
11. Breuillé D., Farge M.C., Rose F., Arnal M., Attaix D., Obled C. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am. J. Physiol. Endocrinol. Metab. 1993, 265:E660-E666.
12. Combaret L., Ralliere C., Taillandier D., Tanaka K., Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol. Biol. Rep. 1999, 26:95-101.
13. Combaret L., Tilignac T., Claustre A., Voisin L., Taillandier D., Obled C., Tanaka K., Attaix D. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats. Biochem. J. 2002, 361:185-192.
14. de Bandt J.P., Chollet-Martin S., Hernvann A., Lioret N., du Roure L.D., Lim S.K., Vaubourdolle M., Guechot J., Saizy R., Giboudeau J. Cytokine response to burn injury: relationship with protein metabolism. J. Trauma 1994, 36:624-628.
15. de Rooij J., Zwartkruis F.J., Verheijen M.H., Cool R.H., Nijman S.M., Wittinghofer A., Bos J.L. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998, 396:474-477.
16. Dehoux M., Gobier C., Lause P., Bertrand L., Ketelslegers J.M., Thissen J.P. IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3β pathways and inhibition of atrogin-1 mRNA. Am. J. Physiol. Endocrinol. Metab. 2007, 292:E145-E150.
17. Deval C., Mordier S., Obled C., Bechet D., Combaret L., Attaix D., Ferrara M. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 2001, 360:143-150.
18. Fang C.H., Tiao G., James J.H., Ogle C., Fischer J.E., Hasselgren P.O. Burn injury stimulates multiple proteolytic pathways in skeletal muscle, including the ubiquitin-energy-dependent pathway. J. Am. Colloid. Surg. 1995, 180:161-170.
19. Fang C.H., Li B.G., Tiao G., Wang J.J., Fischer J.E., Hasselgren P.O. The molecular regulation of protein breakdown following burn injury is different in fast- and slow-twitch skeletal muscle. Int. J. Mol. Med. 1998, 1:163-169.
20. Fang C.H., Li B.G., Wang J.J., Fischer J.E., Hasselgren P.O. Treatment of burned rats with insulin-like growth factor I inhibits the catabolic response in skeletal muscle. Am. J. Physiol. 1998, 275:R1091-R1098.
21. Frost R.A., Lang C.H. Skeletal muscle cytokines: regulation by pathogen-associated molecules and catabolic hormones. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:255-263.
22. Frost R.A., Nystrom G.J., Lang C.H. Epinephrine stimulates IL-6 expression in skeletal muscle and C2C12 myoblasts: role of c-Jun NH2-terminal kinase and histone deacetylase activity. Am. J. Physiol. Endocrinol. Metab. 2004, 286:E809-E817.
23. Gerlo S., Verdood P., Kooijman R. Modulation of cytokine production by cyclic adenosine monophosphate analogs in human leukocytes. J. Interferon Cytokine Res. 2010, 30:883-891.
24. Gilpin D.A. Calculation of a new Meeh constant and experimental determination of burn size. Burns 1996, 22:607-611.
25. Glass D.J. Molecular mechanisms modulating muscle mass. Trends Mol. Med. 2003, 9:344-350.
26. Glass D.J. Signaling pathways perturbing muscle mass. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:225-229.
27. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 2001, 98:14440-14445.
28. Gonçalves D.A., Lira E.C., Baviera A.M., Cao P., Zanon N.M., Arany Z., Bedard N., Tanksale P., Wing S.S., Lecker S.H., Kettelhut I.C., Navegantes L.C. Mechanisms involved in 3',5'-cyclic adenosine monophosphate-mediated inhibition of the ubiquitin-proteasome system in skeletal muscle. Endocrinology 2009, 150:5395-5404.
29. Hart D.W., Wolf S.E., Mlcak R., Chinkes D.L., Ramzy P.I., Obeng M.K., Ferrando A.A., Wolfe R.R., Herndon D.N. Persistence of muscle catabolism after severe burn. Surgery 2000, 128:312-319.
30. Hasselgren P.O., James J.H., Benson D.W., Hall-Angeras M., Angeras U., Hiyama D.T., Li S., Fischer J.E. Total and myofibrillar protein breakdown in different types of rat skeletal muscle: effects of sepsis and regulation by insulin. Metabolism 1989, 38:634-640.
31. Herndon D.N., Tompkins R.G. Support of the metabolic response to burn injury. Lancet 2004, 363:1895-1902.
32. Herndon D.N., Ramzy P.I., DebRoy M.A., Zheng M., Ferrando A.A., Chinkes D.L., Barret J.P., Wolfe R.R., Wolf S.E. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann. Surg. 1999, 229:713-720.
33. Herndon D.N., Hart D.W., Wolf S.E., Chinkes D.L., Wolfe R.R. Reversal of catabolism by beta-blockade after severe burns. N. Engl. J. Med. 2001, 345:1223-1229.
34. Hinkle R.T., Hodge K.M., Cody D.B., Sheldon R.J., Kobilka B.K., Isfort R.J. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002, 25:729-734.
35. Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Isfort R.J. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology 2003, 144:4939-4946.
36. Hinkle R.T., Donnelly E., Cody D.B., Bauer M.B., Sheldon R.J., Isfort R.J. Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J. Muscle Res. Cell Motil. 2004, 25:539-547.
37. Hinkle R.T., Dolan E., Cody D.B., Bauer M.B., Isfort R.J. Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve 2005, 32:775-781.
38. Hinkle R.T., Donnelly E., Cody D.B., Sheldon R.J., Isfort R.J. Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force. J. Appl. Physiol. 2005, 98:655-662.
39. Jeschke M.G., Herndon D.N. Effect of growth factors as therapeutic drugs on hepatic metabolism during the systemic inflammatory response syndrome. Curr. Drug Metab. 2004, 5:399-413.
40. Jeschke M.G., Barrow R.E., Mlcak R.P., Herndon D.N. Endogenous anabolic hormones and hypermetabolism: effect of trauma and gender differences. Ann. Surg. 2005, 241:759-767.
41. Jeschke M.G., Gauglitz G.G., Kulp G.A., Finnerty C.C., Williams F.N., Kraft R., Suman O.E., Mlcak R.P., Herndon D.N. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS ONE 2011, 6:e21245.
42. Kawasaki H., Springett G.M., Mochizuki N., Toki S., Nakaya M., Matsuda M., Housman D.E., Graybiel A.M. A family of cAMP-binding proteins that directly activate Rap1. Science 1998, 282:2275-2279.
43. Lal S.O., Wolf S.E., Herndon D.N. Growth hormone, burns and tissue healing. Growth Horm. IGF Res. 2000, 10(Suppl. B):S39-S43.
44. Lang C.H., Nystrom G.J., Frost R.A. Burn-induced changes in IGF-I and IGF-binding proteins are partially glucocorticoid dependent. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R207-R215.
45. Lania A., Persani L., Ballare E., Mantovani S., Losa M., Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J. Clin. Endocrinol. Metab. 1998, 83:1624-1628.
46. Li B.G., Hasselgren P.O., Fang C.H. Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent mechanisms. Int. J. Biochem. Cell Biol. 2005, 37:2207-2216.
47. Mackenzie K.F., Topping E.C., Bugaj-Gaweda B., Deng C., Cheung Y.F., Olsen A.E., Stockard C.R., High M.L., Baillie G.S., Grizzle W.E., De V.M., Houslay M.D., Wang D., Bolger G.B. Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochem. J. 2008, 411:361-369.
48. McCahill A., Campbell L., McSorley T., Sood A., Lynch M.J., Li X., Yan C., Baillie G.S., Houslay M.D. In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10). Cell Signal. 2008, 20:2071-2083.
49. Mei F.C., Qiao J., Tsygankova O.M., Meinkoth J.L., Quilliam L.A., Cheng X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J. Biol. Chem. 2002, 277:11497-11504.
50. Metrich M., Berthouze M., Morel E., Crozatier B., Gomez A.M., Lezoualc'h F. Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology. Pflugers Arch. 2010, 459:535-546.
51. Meyer N.A., Barrow R.E., Herndon D.N. Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats. J. Trauma 1996, 41:1008-1012.
52. Napolitano L.M. Testosterone administration in male burn patients: the good, the bad, and the ugly. Crit. Care Med. 2001, 29:2032-2033.
53. Pagès L., Gavaldà A., Lehner M.D. PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin. Ther. Pat. 2009, 19:1501-1519.
54. Pereira C.T., Herndon D.N. The pharmacologic modulation of the hypermetabolic response to burns. Adv. Surg. 2005, 39:245-261.
55. Pereira C.T., Murphy K., Jeschke M., Herndon D.N. Post burn muscle wasting and the effects of treatments. Int. J. Biochem. Cell Biol. 2005, 37:1948-1961.
56. Ramzy P.I., Wolf S.E., Herndon D.N. Current status of anabolic hormone administration in human burn injury. JPEN J. Parenter. Enteral Nutr. 1999, 23:S190-S194.
57. Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., MacDonald D., Laliberté F., Liu S., Huang Z., Conti M., Chan C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 2002, 110:1045-1052.
58. Roscioni S.S., Elzinga C.R., Schmidt M. Epac: effectors and biological functions. Naunyn Schmiedebergs Arch. Pharmacol. 2008, 377:345-357.
59. Rutan R.L., Herndon D.N. Growth delay in postburn pediatric patients. Arch. Surg. 1990, 125:392-395.
60. Sakurai Y., Aarsland A., Herndon D.N., Chinkes D.L., Pierre E., Nguyen T.T., Patterson B.W., Wolfe R.R. Stimulation of muscle protein synthesis by long-term insulin infusion in severely burned patients. Ann. Surg. 1995, 222:283-294.
61. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
62. Sheriff S., Joshi R., Friend L.A., James J.H., Balasubramaniam A. Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides 2009, 30:1909-1913.
63. Sheriff S., Kadeer N., Joshi R., Friend L.A., James J.H., Balasubramaniam A. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol. Cell. Endocrinol. 2012, 351:286-295.
64. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 2004, 14:395-403.
65. Strock L.L., Singh H., Abdullah A., Miller J.A., Herndon D.N. The effect of insulin-like growth factor I on postburn hypermetabolism. Surgery 1990, 108:161-164.
66. Wilmore D.W., Long J.M., Mason A.D., Skreen R.W., Pruitt B.A. Catecholamines: mediator of the hypermetabolic response to thermal injury. Ann. Surg. 1974, 180:653-669.